Corbus Pharmaceuticals Holdings, Inc. (CRBP) shareholders
Close on Nov 17, 2026Market cap $58.22MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Cormorant Asset Management, LP Joint filing with Chen Bihua (13.36%) | 2,344,971 | 13.36% | 13G (passive) amendment | Dec 11, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 1,914,788 | 9.90% | 13G (passive) | Sep 23, 2026 |
| Chen Bihua Joint filing with Cormorant Asset Management, LP (7.76%) | 1,500,000 | 7.76% | 13G (passive) amendment | Oct 31, 2026 |
| Cormorant Global Healthcare GP, LLC | 1,475,000 | – | 13G (passive) | Jan 26, 2024 |
| abrdn Inc. Joint filing with Aberdeen Group plc (7.53%) | 1,321,750 | 7.53% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 1,093,434 | 5.90% | 13G (passive) | Jun 30, 2026 |
| OrbiMed Capital LLC | 718,200 | 5.90% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,344,971 | 12.12% | $22.00M | – | 1.13% |
| Orbimed Advisors LLC | 1,737,287 | 8.98% | $16.30M | – | 0.30% |
| BlackRock, Inc. | 1,331,135 | 6.88% | $12.49M | +1,059,499 | 0.00% |
| abrdn plc | 1,321,750 | 6.83% | $12.40M | – | 0.02% |
| Vanguard Capital Management LLC | 760,940 | 3.93% | $7.14M | +26,834 | 0.00% |
| Jones Hill Capital LP | 653,572 | 3.38% | $6.13M | New | 1.30% |
| Prosight Management, LP | 650,000 | 3.36% | $6.10M | −47,108 | 1.05% |
| Stonepine Capital Management, LLC | 425,000 | 2.20% | $3.99M | +41,538 | 2.25% |
| Geode Capital Management, LLC | 423,374 | 2.19% | $3.97M | +236,345 | 0.00% |
| ADAR1 Capital Management, LLC | 421,787 | 2.18% | $3.96M | +90,006 | 0.18% |
| Diadema Partners LP | 301,264 | 1.56% | $2.83M | −138,693 | 0.36% |
| Susquehanna International Group, Llp | 293,203 | 1.52% | $2.75M | −40,212 | 0.00% |
| State Street Corp | 254,672 | 1.32% | $2.39M | +185,800 | 0.00% |
| Dimensional Fund Advisors LP | 190,214 | 0.98% | $1.78M | +53,612 | 0.00% |
| Exome Asset Management LLC | 184,914 | 0.96% | $1.73M | −49,222 | 1.07% |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 151,640 | 0.78% | $1.42M | −8,822 | 0.00% |
| Jane Street Group, LLC | 139,133 | 0.72% | $1.31M | +65,940 | 0.00% |
| Northern Trust Corp | 124,906 | 0.65% | $1.17M | +83,402 | 0.00% |
| Vanguard Fiduciary Trust Co | 112,397 | 0.58% | $1.05M | +16,156 | 0.00% |
| Vanguard Portfolio Management LLC | 111,302 | 0.58% | $1.04M | +86,937 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 107 | 14M | 71.4% | 24 / 29 | 26 / 23 | 4M | 3M |
| Q1 2026 | 107 | 13M | 66.3% | 24 / 33 | 22 / 13 | 3M | 2M |
| Q4 2025 | 101 | 13M | 68.9% | 29 / 25 | 23 / 9 | 6M | 1M |
| Q3 2025 | 81 | 9M | 45.5% | 16 / 16 | 25 / 15 | 1M | 1M |
| Q2 2025 | 80 | 9M | 46.9% | 15 / 17 | 29 / 21 | 1M | 2M |
| Q1 2025 | 86 | 10M | 53.9% | 17 / 23 | 24 / 29 | 2M | 2M |
| Q4 2024 | 99 | 11M | 56.6% | 21 / 34 | 22 / 26 | 2M | 2M |
| Q3 2024 | 107 | 12M | 60.8% | 31 / 39 | 20 / 30 | 5M | 3M |
| Q2 2024 | 107 | 11M | 55.6% | 41 / 23 | 24 / 15 | 4M | 2M |
| Q1 2024 | 82 | 9M | 46.2% | 52 / 15 | 6 / 3 | 8M | 0M |
| Q4 2023 | 34 | 1M | 3.9% | 8 / 4 | 7 / 1 | 0M | 0M |
| Q3 2023 | 27 | 1M | 3.8% | 3 / 7 | 5 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
71 funds held CRBP in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 533,575 | 2.76% | $5.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 406,966 | 2.10% | $3.82M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 208,310 | 1.08% | $1.95M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 179,556 | 0.93% | $1.61M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 157,182 | 0.81% | $1.47M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 83,288 | 0.43% | $658.81K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 58,383 | 0.30% | $523.70K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 55,352 | 0.29% | $519.20K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 39,702 | 0.21% | $356.13K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 31,546 | 0.16% | $282.97K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 30,772 | 0.16% | $288.64K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 27,193 | 0.14% | $215.10K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 26,811 | 0.14% | $240.49K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 23,576 | 0.12% | $186.49K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 23,002 | 0.12% | $215.76K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yuval Cohen | Chief Executive Officer, Director | 157,316 | 0.81% | Aug 10, 2026 |
| Leonardo Viana Nicacio | Chief Medical Officer | 58,333 | 0.30% | Aug 17, 2026 |
| Nishant C. Saxena | Chief Business Officer | 77,900 | 0.40% | Aug 12, 2026 |
| Sean F. Moran | Chief Financial Officer | 84,694 | 0.44% | Aug 10, 2026 |
| Dominic Smethurst | Chief Medical Officer | 89,790 | 0.46% | Mar 4, 2026 |
| Ian Hodgson | Chief Operating Officer | 51,080 | 0.26% | Feb 18, 2026 |
| Yong Ben | Director | 9,383 | 0.05% | Sep 15, 2026 |
| John Kenneth Jenkins | Director | 3,833 | 0.02% | Jun 11, 2026 |
| Anne Altmeyer | Director | 7,579 | 0.04% | Jun 11, 2026 |
| Winston Kung | Director | 12,140 | 0.06% | Jun 11, 2026 |
| Brent Pfeiffenberger | Director | 7,500 | 0.04% | May 21, 2026 |
| Rachelle Suzanne Jacques | Director | 11,383 | 0.06% | May 21, 2026 |
| Alan F. Holmer | Director | 10,629 | 0.05% | Jun 2, 2025 |
| Bihua Chen | – | 2,344,971 | 12.12% | Nov 2, 2026 |
| Cormorant Asset Management, LP | – | 1,919,971 | 9.93% | Nov 2, 2026 |
| Cormorant Global Healthcare Master Fund, LP | – | 2,349,231 | 12.15% | Nov 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP – | Oct 29, 2026 | Sale | −425,000 | $4.10 | $1.74M | 1,919,971 |
| Yong Ben Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,000 | $7.84 | $15.68K | 9,383 |
| Leonardo Viana Nicacio Chief Medical Officer | Aug 16, 2026 | Award | +58,333 | – | – | 58,333 |
| Nishant C. Saxena Chief Business Officer | Aug 11, 2026 | Buy | +2,600 | $9.63 | $25.04K | 77,900 |
| Yuval Cohen Chief Executive Officer, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −17,000 | $10.08 | $171.36K | 157,316 |
| Sean F. Moran Chief Financial Officer | Aug 7, 2026 | Sale(10b5-1 plan) | −12,000 | $10.08 | $120.96K | 84,694 |
| Anne Altmeyer Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,412 | $7.91 | $19.08K | 7,579 |
| John Kenneth Jenkins Director | Jun 10, 2026 | Sale(10b5-1 plan) | −4,800 | $7.91 | $37.97K | 3,833 |
| Winston Kung Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,026 | $7.91 | $16.03K | 12,140 |
| Nishant C. Saxena Chief Business Officer | Jun 3, 2026 | Buy | +9,000 | $7.58 | $68.22K | 75,300 |
| Nishant C. Saxena Chief Business Officer | Jun 2, 2026 | Buy | +4,500 | $7.33 | $32.99K | 66,300 |
| Nishant C. Saxena Chief Business Officer | May 21, 2026 | Award | +58,300 | – | – | 61,800 |
| Anne Altmeyer Director | May 19, 2026 | Award | +3,800 | – | – | 9,991 |
| John Kenneth Jenkins Director | May 19, 2026 | Award | +3,800 | – | – | 8,633 |
| Yong Ben Director | May 19, 2026 | Award | +3,800 | – | – | 11,383 |
| Winston Kung Director | May 19, 2026 | Award | +3,800 | – | – | 14,166 |
| Rachelle Suzanne Jacques Director | May 19, 2026 | Award | +3,800 | – | – | 11,383 |
| Brent Pfeiffenberger Director | May 19, 2026 | Award | +7,500 | – | – | 7,500 |
| Dominic Smethurst Chief Medical Officer | Mar 2, 2026 | Sale | −6,097 | $8.30 | $50.61K | 89,790 |
| Ian Hodgson Chief Operating Officer | Feb 17, 2026 | Sale | −847 | $7.38 | $6.25K | 51,080 |
| Sean F. Moran Chief Financial Officer | Feb 13, 2026 | Sale(10b5-1 plan) | −4,701 | $7.78 | $36.57K | 96,694 |
| Yuval Cohen Chief Executive Officer, Director | Feb 13, 2026 | Sale(10b5-1 plan) | −13,871 | $7.78 | $107.92K | 174,316 |
| Dominic Smethurst Chief Medical Officer | Feb 3, 2026 | Sale | −3,285 | $8.09 | $26.58K | 95,887 |
| Ian Hodgson Chief Operating Officer | Feb 3, 2026 | Sale | −2,415 | $8.09 | $19.54K | 51,927 |
| Yuval Cohen Chief Executive Officer, Director | Jan 14, 2026 | Award | +50,000 | – | – | 188,187 |
| Ian Hodgson Chief Operating Officer | Jan 14, 2026 | Award | +28,365 | – | – | 54,342 |
| Sean F. Moran Chief Financial Officer | Jan 14, 2026 | Award | +28,082 | – | – | 101,395 |
| Dominic Smethurst Chief Medical Officer | Jan 14, 2026 | Award | +28,365 | – | – | 99,172 |
| Bihua Chen 10% owner | Dec 11, 2025 | Sale | −30,029 | $11.46 | $344.13K | 2,344,971 |
| Yuval Cohen Chief Executive Officer, Director | Oct 27, 2025 | Option exercise | +8,973 | $4.26 | $38.22K | 147,160 |
| Yuval Cohen Chief Executive Officer, Director | Oct 27, 2025 | Sale(10b5-1 plan) | −8,973 | $17.14 | $153.80K | 138,187 |
| Sean F. Moran Chief Financial Officer | Oct 24, 2025 | Option exercise | +12,981 | $4.26 | $55.30K | 86,294 |
| Sean F. Moran Chief Financial Officer | Oct 24, 2025 | Sale(10b5-1 plan) | −12,981 | $17.02 | $220.94K | 73,313 |
| Yuval Cohen Chief Executive Officer, Director | Oct 24, 2025 | Option exercise | +18,660 | $4.26 | $79.49K | 156,847 |
| Yuval Cohen Chief Executive Officer, Director | Oct 24, 2025 | Sale(10b5-1 plan) | −18,660 | $17.01 | $317.41K | 138,187 |
| Anne Altmeyer Director | Oct 20, 2025 | Sale(10b5-1 plan) | −1,060 | $20.50 | $21.73K | 6,191 |
| Anne Altmeyer Director | Oct 20, 2025 | Option exercise | +1,060 | $4.80 | $5.09K | 7,251 |
| Yong Ben Director | May 30, 2025 | Award | +4,800 | – | – | 7,583 |
| Anne Altmeyer Director | May 30, 2025 | Award | +4,800 | – | – | 6,191 |
| Anne Altmeyer Director | May 30, 2025 | Sale(10b5-1 plan) | −1,392 | $7.25 | $10.09K | 1,391 |
| Winston Kung Director | May 30, 2025 | Award | +4,800 | – | – | 10,366 |
| Alan F. Holmer Director | May 30, 2025 | Award | +4,800 | – | – | 10,629 |
| Rachelle Suzanne Jacques Director | May 30, 2025 | Award | +4,800 | – | – | 7,583 |
| John Kenneth Jenkins Director | May 30, 2025 | Sale(10b5-1 plan) | −2,783 | $7.35 | $20.46K | 33 |
| John Kenneth Jenkins Director | May 30, 2025 | Award | +4,800 | – | – | 4,833 |
| Dominic Smethurst Chief Medical Officer | Mar 6, 2025 | Sale | −6,393 | $6.78 | $43.34K | 70,807 |
| Yuval Cohen Chief Executive Officer, Director | Feb 14, 2025 | Sale(10b5-1 plan) | −7,134 | $8.76 | $62.49K | 138,187 |
| Sean F. Moran Chief Financial Officer | Feb 14, 2025 | Sale(10b5-1 plan) | −2,792 | $8.76 | $24.46K | 73,313 |
| Yuval Cohen Chief Executive Officer, Director | Jan 31, 2025 | Award | +68,100 | – | – | 145,321 |
| Sean F. Moran Chief Financial Officer | Jan 31, 2025 | Award | +27,500 | – | – | 76,105 |
| Dominic Smethurst Chief Medical Officer | Jan 31, 2025 | Award | +27,200 | – | – | 77,200 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +47,564 | $21.47 | $1.02M | 2,349,231 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +66,088 | $19.61 | $1.30M | 2,162,116 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +139,551 | $20.42 | $2.85M | 2,301,667 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +25,769 | $22.23 | $572.84K | 2,375,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +45,085 | $17.48 | $788.09K | 2,070,085 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +25,943 | $18.36 | $476.31K | 2,096,028 |
| Winston Kung Director | Aug 16, 2024 | Award | +5,566 | – | – | 5,566 |
| Yuval Cohen Chief Executive Officer, Director | Jun 18, 2024 | Sale(10b5-1 plan) | −7,179 | $42.24 | $303.24K | 77,221 |
| Yuval Cohen Chief Executive Officer, Director | Jun 18, 2024 | Option exercise | +1,770 | $14.10 | $24.96K | 86,170 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Corbus Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,526 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stifel, Nicolaus & Company, Inc CIAS /FA Officer | Aug 7, 2026 | 17,000 | $171.40K | Aug 7, 2026 | Restricted Stock Units |
| Stifel, Nicolaus & Company, Inc CIAS /FA Officer | Aug 7, 2026 | 12,000 | $120.97K | Aug 7, 2026 | Restricted Stock Units |
| Dominic Smethurst Officer | Jul 27, 2026 | 23,025 | $211.82K | Jul 27, 2026 | Restricted Stock Units |
| Dominic Smethurst Officer | Mar 2, 2026 | 6,097 | $50.60K | Mar 2, 2026 | Restricted Stock Units |
| Yuval Cohen Officer | Feb 13, 2026 | 20,000 | $812.60K | Feb 13, 2026 | Restricted Stock Units |
| Yuval Cohen Officer | Oct 24, 2025 | 27,633 | $469.98K | Oct 24, 2025 | Stock Option Exercise |
| Sean F. Moran Officer | Oct 24, 2025 | 12,981 | $220.92K | Oct 24, 2025 | Stock Option Exercise |
| Dominic Smethurst Officer | Mar 6, 2025 | 6,393 | $43.73K | Mar 6, 2025 | Restricted Stock Units |
| Sean F. Moran Officer | Feb 14, 2025 | 2,792 | $26.47K | Feb 14, 2025 | Restricted Stock Units |
| Yuval Cohen Officer | Feb 14, 2025 | 7,134 | $67.63K | Feb 14, 2025 | Restricted Stock Units |
| Avery W. Catlin Director | Sep 4, 2024 | 888 | $50.11K | Sep 4, 2024 | Option Exercise |
| Sean F. Moran Officer | Jun 14, 2024 | 18,043 | $954.29K | Jun 14, 2024 | Options |
| Yuval Cohen Officer | Jun 14, 2024 | 63,358 | $3.35M | Jun 14, 2024 | Owned Shares |
| Brake Rachael Louise Former Chief Scientific Officer | May 8, 2024 | 15,550 | $634.88K | May 8, 2024 | Option Exercise |
See a number that looks wrong?